CG Oncology
Financials
Estimates*
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 10.4m | <1m | <1m | 1.4m | 7.2m | 87.7m |
| % growth | - | (98 %) | (47 %) | 1277 % | 415 % | 1126 % |
| EBITDA | (12.6m) | (35.2m) | (55.4m) | (103m) | (127m) | (62.7m) |
| % EBITDA margin | (122 %) | (18446 %) | (54990 %) | (7450 %) | (1780 %) | (71 %) |
| Profit | (12.8m) | (35.4m) | (48.6m) | (85.9m) | (116m) | (108m) |
| % profit margin | (124 %) | (18555 %) | (48224 %) | (6189 %) | (1625 %) | (123 %) |
| EV / revenue | - | - | 29960.3x | 1695.2x | 327.7x | 25.6x |
| EV / EBITDA | - | - | -54.5x | -22.8x | -18.4x | -35.8x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$13.6m | Series A | ||
$10.0m | Series B | ||
$22.0m | Series C | ||
$47.0m | Series D | ||
* | $120m | Series E | |
* | $105m Valuation: $600m 3141.4x EV/LTM Revenues -17.0x EV/LTM EBITDA | Late VC | |
* | N/A | $380m Valuation: $1.2b -21.8x EV/LTM EBITDA | IPO |
| Total Funding | AUD491m | ||
Related Content
Recent News about CG Oncology
EditCG Oncology is a healthcare startup that specializes in oncolytic immunotherapy, a type of treatment that uses the body's immune system to fight cancer. The company's primary focus is on developing treatments that can save the bladder in patients suffering from bladder cancer. Their mission is to improve the quality of life for patients with urologic cancers, allowing them to live and work with dignity.
Their leading product, cretostimogene grenadenorepvec, is an innovative immunotherapy treatment that is delivered directly into the bladder. This treatment has shown potential in treating Non-Muscle Invasive Bladder Cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG), a common treatment for bladder cancer. The side effects of this treatment are in line with other similar therapies.
CG Oncology operates in the healthcare market, specifically in the field of oncology. Their business model revolves around the research, development, and commercialization of their immunotherapy treatments. They generate revenue through the sales of these treatments to healthcare providers and patients.
Recently, the company announced that they will be presenting interim Phase 3 data from their BOND-003 study at the upcoming 24th Annual Meeting of the Society of Urologic Oncology. They have also recently appointed new members to their executive team, including a new President and Chief Operating Officer, Chief Technical Officer, and Chief Medical Officer.
Keywords: Oncology, Immunotherapy, Bladder Cancer, Urologic Cancers, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer, Healthcare Market, Research and Development, Commercialization, Executive Team.